Shanghai, China – March 20, 2026 – MicroPort® Endovastec™ announced that its HawkMaster™ Detachable Fibered Embolization Coils (HawkMaster™) have received marketing approval from China’s National Medical Products Administration (NMPA).
HawkMaster™ is indicated for the embolization of peripheral arterial aneurysms, arteriovenous malformations (AVMs), and arteriovenous fistulas (AVFs), offering an additional treatment option for embolization therapy. These vascular conditions can lead to serious complications, including hemorrhage, tissue ischemia, and, in severe cases, heart failure. Despite advances in interventional therapy, effective and versatile embolization tools remain essential to support treatment across a range of complex anatomies.
HawkMaster™ is designed to support a wide range of clinical scenarios through its structural design and delivery options. The device features a platinum-tungsten coil with dense fibers and an interlocking structure, providing radiopacity, MRI compatibility, and biocompatibility.
It is available in both 0.018” and 0.035” delivery systems and includes multiple configurations to support procedural needs:
A broad range of sizes further enables treatment across varying vessel diameters and complex anatomies.
HawkMaster™ incorporates a controlled mechanical detachment mechanism, allowing repositioning prior to deployment to support precise placement. Once the detachment zone passes the catheter’s tip, the coil is released instantly without additional steps, helping streamline the procedure. The device also demonstrates good catheter compatibility and trackability, supporting delivery stability and flexibility in catheter selection.
“The NMPA’s approval of HawkMaster™ represents an important addition to our embolization portfolio, following HawkNest™ Fibered Embolization Coils. It further strengthens our offering in peripheral vascular interventions” said Qing Zhu, PhD, President of MicroPort® Endovastec™.
About MicroPort® Endovastec™
Founded in 2012, MicroPort®Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on the research, development, manufacturing, and commercialization of aortic, peripheral vascular and tumor interventional devices.
MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters, snare retrieval kits, thrombectomy device, and tumor embolization microspheres. The company is committed to advancing emerging technologies in great vessel surgery and peripheral vascular medicine and to providing access to state-of-the-art solutions for patients worldwide.
More information is available at: www.endovastec.com/en
Regulatory disclaimer
The HawkMaster™ Detachable Fibered Embolization Coils have received marketing approval from the NMPA in China. Regulatory status varies by country and region. Not all products or indications described in this release may be approved in all markets. Healthcare professionals should refer to applicable local regulatory requirements and instructions for use.
References
Data on file, MicroPort® Endovastec™. Clinical trial ongoing; results pending.